Clinical reactivation after liver transplantation with an unusual minor strain of hepatitis B virus in an occult carrier

Liver Transplantation

Volumn 12, Issue 8, 2006, Pages 1283-1289

  Zöllner, Bernhard ^a   Feucht, Heinz Hubert ^a   Sterneck, Martina ^a   Schäfer, Hansjörg ^a   Rogiers, Xavier ^a   Fischer, Lutz ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RAPAMYCIN; VIRUS DNA;

ADULT; ARTERY OCCLUSION; ARTICLE; CASE REPORT; CHEMOPROPHYLAXIS; DIAGNOSTIC PROCEDURE; EXPLANT; GENE INSERTION; HEPATIC ARTERY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REINFECTION; RETRANSPLANTATION; SEROLOGY; VIRUS CARRIER; VIRUS ISOLATION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN;

CARRIER STATE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHYLOGENY; REOPERATION; VIRUS ACTIVATION;

EID: 33746918398     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20858     Document Type: Article

References (20)

1. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26: 517-526.
2. Egwim C, Botero RC. Is hepatitis B immunoglobulin prophylaxis needed for liver transplantation in the era of new antivirals? Transplant Proc 2005;37:2200-2204.
3. Lok ASF. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002;8(Suppl 1):S67-S73.
4. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003;38:86-95.
5. Han SHB, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741-748.
6. Fischer L, Sterneck M, Zöllner B, Rogiers X. Lamivudine improves the prognosis of patients with hepatitis B after liver transplantation. Transplant Proc 2000;32:2128-2130.
7. Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wisner RH, Douglas DD. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003;9:1253-1257.
8. Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. "Occult" hepatitis B virus as a source of infection in liver transplant recipients. Lancet 1994;343:142-146.
9. Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: Low risk of HBV reactivation. Transplantation 2005;79:1631-1633.
10. Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: Clinical significance. Liver Transpl 2004;10:356-362.
11. Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, et al. Viral features of lamivudine resistant hepatitis B virus genotypes A and D. Hepatology 2004;39:42-50.
12. Douglas DD, Rakela J, Taswell HF, Krom RAF, Wiesner RH. Hepatitis B virus replication patterns after orthotopic liver transplantation: De novo versus recurrent infection. Transplant Proc 1993;25:1755-1757.
13. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology 2001;34:194-203.
14. Zöllner B. Surveillance of the molecular epidemiology of hepatitis B virus in industrialized countries: Necessary despite low prevalence and an available, effective vaccine? Clin Infect Dis 2004;39:953-954.
15. Crespo J, Fabrega E, Casafont F, Rivero M, de las Heras G, de la Pena J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999;5:175-183.
16. Segovia R, Sanchez-Fueyo A, Rimola A, Grande L, Bruguera M, Costa J, et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001:7:106-112.
17. Preikschat P, Meisel H, Will H, Günther S. Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. J Gen Virol 1999;80:2685-2691.
18. Tai DI, Chung ZJ, Chen CL, Eng HL. Reappearance of HBsAg with compartimentalized different HBV strains in allograft versus PBMC of the recipient. J Gastroenterol 2001;36:200-205.
19. Stoll-Becker S, Repp R, Glebe D, Schaefer S, Kreuder J, Kann M, et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J Virol 1997;71:5399-5407.
20. Mason A, Theal J, Bain V, Adams E, Perrillo R. Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease. Am J Gastroenterol 2005;100:972-976.